Global Gaucher Disease Treatment Market Outlook 2027
Global Gaucher Disease Market Analysis – 2018-2027
Gaucher disease (GD) refers to the accumulation of glucocerebroside in cells and certain organs leading to the enlargement of the liver and spleen. The genetic disorder is caused by a hereditary deficiency of the enzyme glucocerebrosidase and is characterized by bruising, fatigue, anemia and low blood platelet count. The global Gaucher disease market is anticipated to record a CAGR of around 3% over the forecast period, i.e. 2019-2026. Factors such as increasing incidences of Gaucher’s disease as well as the increasing focus of the pharmaceutical companies on introducing new products that cater to the treatment of Gaucher disease are anticipated to contribute significantly towards the growth of the global Gaucher disease market. Additionally, increasing concern for the growing incidences of Gaucher disease amongst people around the globe, coupled with the growing support and funding of the government of nations and the rising per capita expenditure on healthcare by several nations around the globe are some of the factors anticipated to drive the growth of the global Gaucher disease market.
The global Gaucher disease market consists of various segments that are segmented by product type, by infusion mode, by clinical type, by end user and by region. The product type segment is further sub-divided into enzyme replacement therapy or ERT and substrate replacement therapy or SRT. Out of these, the enzyme replacement therapy segment, which held a market value of around USD 1400 million in the year 2018, is anticipated to grow with a CAGR of around 3% during the forecast period. On the basis of infusion mode, the market is segmented into intravenous infusion and oral. Out of these segments, the intravenous infusion segment is anticipated to hold the largest market share by the end of 2026 and is anticipated to grow with a CAGR of around 3% during the forecast period and reach a value of around USD 1600 million by the end of 2026.
Based on region, the global Gaucher disease market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa. The market in Europe, which had accounted for around 28% share in the year 2018, is estimated to witness a CAGR of around 2% during the forecast period and reach a value of around USD 520 million by the end of 2026.
Some of the affluent industry leaders in the global Gaucher disease market are Protalix Inc., Pfizer Inc., Actelion Pharmaceuticals Ltd., Sanofi and Takeda Pharmaceutical Company Limited.
Gaucher disease (GD) refers to the accumulation of glucocerebroside in cells and certain organs leading to the enlargement of the liver and spleen. The genetic disorder is caused by a hereditary deficiency of the enzyme glucocerebrosidase and is characterized by bruising, fatigue, anemia and low blood platelet count. The global Gaucher disease market is anticipated to record a CAGR of around 3% over the forecast period, i.e. 2019-2026. Factors such as increasing incidences of Gaucher’s disease as well as the increasing focus of the pharmaceutical companies on introducing new products that cater to the treatment of Gaucher disease are anticipated to contribute significantly towards the growth of the global Gaucher disease market. Additionally, increasing concern for the growing incidences of Gaucher disease amongst people around the globe, coupled with the growing support and funding of the government of nations and the rising per capita expenditure on healthcare by several nations around the globe are some of the factors anticipated to drive the growth of the global Gaucher disease market.
The global Gaucher disease market consists of various segments that are segmented by product type, by infusion mode, by clinical type, by end user and by region. The product type segment is further sub-divided into enzyme replacement therapy or ERT and substrate replacement therapy or SRT. Out of these, the enzyme replacement therapy segment, which held a market value of around USD 1400 million in the year 2018, is anticipated to grow with a CAGR of around 3% during the forecast period. On the basis of infusion mode, the market is segmented into intravenous infusion and oral. Out of these segments, the intravenous infusion segment is anticipated to hold the largest market share by the end of 2026 and is anticipated to grow with a CAGR of around 3% during the forecast period and reach a value of around USD 1600 million by the end of 2026.
Based on region, the global Gaucher disease market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa. The market in Europe, which had accounted for around 28% share in the year 2018, is estimated to witness a CAGR of around 2% during the forecast period and reach a value of around USD 520 million by the end of 2026.
Some of the affluent industry leaders in the global Gaucher disease market are Protalix Inc., Pfizer Inc., Actelion Pharmaceuticals Ltd., Sanofi and Takeda Pharmaceutical Company Limited.
Global Gaucher Disease Market
1. INTRODUCTION
1.1. MARKET DEFINITION
1.2. PURPOSE OF THE REPORT
1.3. CURRENCY
1.4. LIMITATIONS
1.5. STAKEHOLDERS
2. RESEARCH METHODOLOGY
2.1. RESEARCH SCOPE
2.2. MARKET SEGMENTATION
2.3. RESEARCH APPROACH
2.3.1 TOP-DOWN APPROACH
2.3.2 BOTTOM-UP APPROACH
2.4. PRIMARY RESEARCH
2.5. SECONDARY RESEARCH
2.6. ASSUMPTIONS
3. GLOBAL GAUCHER DISEASE MARKET – EXECUTIVE SUMMARY
3.1. SUMMARY
4. GLOBAL GAUCHER DISEASE MARKET OVERVIEW
4.1. MARKET DYNAMICS
4.1.1 DRIVING FORCES
4.1.1.1 Growing incidence of Gaucher disease
4.1.1.2 Increasing governmental support and growing demand for enzyme
replacement therapy for the treatment of rare diseases
4.1.2 RESTRAINING FACTOR
4.1.2.1 High cost of product and therapies
4.1.3 OPPORTUNITY MATRIX
4.1.3.1 Expansion of product portfolio especially in towards Pharmaceutical Products
5. INDUSTRY INSIGHTS
5.1. PORTER'S FIVE FORCES ANALYSIS
5.1.1 BARGAINING POWER OF SUPPLIER
5.1.2 BARGAINING POWER OF BUYER
5.1.3 THREAT OF SUBSTITUTE
5.1.4 THREAT OF NEW ENTRANT
5.1.5 DEGREE OF COMPETITION
5.2. VALUE CHAIN ANALYSIS
6. GLOBAL GAUCHER DISEASE MARKET, BY PRODUCT
6.1. OVERVIEW
7. GLOBAL GAUCHER DISEASE MARKET, BY INFUSION MODES
7.1. OVERVIEW
8. GLOBAL GAUCHER DISEASE MARKET, BY DISTRIBUTION CHANNEL
8.1. OVERVIEW
9. GLOBAL GAUCHER DISEASE MARKET, BY CLINICAL TYPE
9.1. OVERVIEW
10. NORTH AMERICA GAUCHER DISEASE MARKET
10.1. OVERVIEW
10.1.1.1 North America Market Analysis, By Product Type
10.1.1.2 North America Market Analysis, By Intake Mode
10.1.1.3 North America Market Analysis, By Clinical Types
10.1.1.4 North America Market Analysis, By End-Users
10.2. U.S.
10.2.1.1 U.S. Market Analysis, By Product Type
10.2.1.2 U.S. Market Analysis, By Intake Mode
10.2.1.3 U.S. Market Analysis, By Clinical Types
10.2.1.4 U.S. Market Analysis, By End-Users
10.3. CANADA
10.3.1.1 Canada Market Analysis, By Product Type
10.3.1.2 Canada Market Analysis, By Intake Mode
10.3.1.3 Canada Market Analysis, By Clinical Types
10.3.1.4 Canada Market Analysis, By End-Users
11. LATIN AMERICA GAUCHER DISEASE MARKET
11.1. OVERVIEW
11.1.1.1 Latin America Market Analysis, By Product Type
11.1.1.2 Latin America Market Analysis, By Intake Mode
11.1.1.3 Latin America Market Analysis, By Clinical Types
11.1.1.4 Latin America Market Analysis, By End-Users
11.2. BRAZIL
11.2.1.1 Brazil Market Analysis, By Product Type
11.2.1.2 Brazil Market Analysis, By Intake Mode
11.2.1.3 Brazil Market Analysis, By Clinical Types
11.2.1.4 Brazil Market Analysis, By End-Users
11.3. MEXICO
11.3.1.1 Mexico Market Analysis, By Product Type
11.3.1.2 Mexico Market Analysis, By Intake Mode
11.3.1.3 Mexico Market Analysis, By Clinical Types
11.3.1.4 Mexico Market Analysis, By End-Users
11.4. ARGENTINA
11.4.1.1 Argentina Market Analysis, By Product Type
11.4.1.2 Argentina Market Analysis, By Intake Mode
11.4.1.3 Argentina Market Analysis, By Clinical Types
11.4.1.4 Argentina Market Analysis, By End-Users
12. EUROPE GAUCHER DISEASE MARKET
12.1. OVERVIEW
12.1.1.1 Europe Market Analysis, By Product Type
12.1.1.2 Europe Market Analysis, By Intake Mode
12.1.1.3 Europe Market Analysis, By Clinical Types
12.1.1.4 Europe Market Analysis, By End-Users
12.2. GERMANY
12.2.1.1 Germany Market Analysis, By Product Type
12.2.1.2 Germany Market Analysis, By Intake Mode
12.2.1.3 Germany Market Analysis, By Clinical Types
12.2.1.4 Germany Market Analysis, By End-Users
12.3. UNITED KINGDOM
12.3.1.1 United Kingdom Market Analysis, By Product Type
12.3.1.2 United Kingdom Market Analysis, By Intake Mode
12.3.1.3 United Kingdom Market Analysis, By Clinical Types
12.3.1.4 United Kingdom Market Analysis, By End-Users
12.4. FRANCE
12.4.1.1 France Market Analysis, By Product Type
12.4.1.2 France Market Analysis, By Intake Mode
12.4.1.3 France Market Analysis, By Clinical Types
12.4.1.4 France Market Analysis, By End-Users
12.5. ITALY
12.5.1.1 Italy Market Analysis, By Product Type
12.5.1.2 Italy Market Analysis, By Intake Mode
12.5.1.3 Italy Market Analysis, By Clinical Types
12.5.1.4 Italy Market Analysis, By End-Users
12.6. SPAIN
12.6.1.1 Spain Market Analysis, By Product Type
12.6.1.2 Spain Market Analysis, By Intake Mode
12.6.1.3 Spain Market Analysis, By Clinical Types
12.6.1.4 Spain Market Analysis, By End-Users
12.7. TURKEY
12.7.1.1 Turkey Market Analysis, By Product Type
12.7.1.2 Turkey Market Analysis, By Intake Mode
12.7.1.3 Turkey Market Analysis, By Clinical Types
12.7.1.4 Turkey Market Analysis, By End-Users
12.8. RUSSIA
12.8.1.1 Russia Market Analysis, By Product Type
12.8.1.2 Russia Market Analysis, By Intake Mode
12.8.1.3 Russia Market Analysis, By Clinical Types
12.8.1.4 Russia Market Analysis, By End-Users
13. ASIA PACIFIC GAUCHER DISEASE MARKET
13.1. OVERVIEW
13.1.1.1 Asia Pacific Market Analysis, By Product Type
13.1.1.2 Asia Pacific Market Analysis, By Intake Mode
13.1.1.3 Asia Pacific Market Analysis, By Clinical Types
13.1.1.4 Asia Pacific Market Analysis, By End-Users
13.2. CHINA
13.2.1.1 China Market Analysis, By Product Type
13.2.1.2 China Market Analysis, By Intake Mode
13.2.1.3 China Market Analysis, By Clinical Types
13.2.1.4 China Market Analysis, By End-Users
13.3. INDIA
13.3.1.1 India Market Analysis, By Product Type
13.3.1.2 India Market Analysis, By Intake Mode
13.3.1.3 India Market Analysis, By Clinical Types
13.3.1.4 India Market Analysis, By End-Users
13.4. JAPAN
13.4.1.1 Japan Market Analysis, By Product Type
13.4.1.2 Japan Market Analysis, By Intake Mode
13.4.1.3 Japan Market Analysis, By Clinical Types
13.4.1.4 Japan Market Analysis, By End-Users
13.5. SOUTH KOREA
13.5.1.1 South Korea Market Analysis, By Product Type
13.5.1.2 South Korea Market Analysis, By Intake Mode
13.5.1.3 South Korea Market Analysis, ByClinical Types
13.5.1.4 South Korea Market Analysis, By End-Users
13.6. AUSTRALIA
13.6.1.1 Australia Market Analysis, By Product Type
13.6.1.2 Australia Market Analysis, By Intake Mode
13.6.1.3 Australia Market Analysis, By Clinical Types
13.6.1.4 Australia Market Analysis, By End-Users
14. MIDDLE EAST AND AFRICA (MEA) GAUCHER DISEASE MARKET
14.1. OVERVIEW
14.1.1.1 MEA Market Analysis, By Product Type
14.1.1.2 MEA Market Analysis, By Intake Mode
14.1.1.3 MEA Market Analysis, By Clinical Types
14.1.1.4 MEA Market Analysis, By End-Users
14.2. SOUTH AFRICA
14.2.1.1 South Africa Market Analysis, By Product Type
14.2.1.2 South Africa Market Analysis, By Intake Mode
14.2.1.3 South Africa Market Analysis, By Clinical Types
14.2.1.4 South Africa Market Analysis, By End-Users
14.3. SAUDI ARABIA
14.3.1.1 Saudi Arabia Market Analysis, By Product Type
14.3.1.2 Saudi Arabia Market Analysis, By Intake Mode
14.3.1.3 Saudi Arabia Market Analysis, By Clinical Types
14.3.1.4 Saudi Arabia Market Analysis, By End-Users
14.4. ISRAEL
14.4.1.1 Israel Market Analysis, By Product Type
14.4.1.2 Israel Market Analysis, By Intake Mode
14.4.1.3 Israel Market Analysis, By Clinical Types
14.4.1.4 Israel Market Analysis, By End-Users
14.5. UAE
14.5.1.1 UAE Market Analysis, By Product Type
14.5.1.2 UAE Market Analysis, By Intake Mode
14.5.1.3 UAE Market Analysis, By Clinical Types
14.5.1.4 UAE Market Analysis, By End-Users
15. COMPANY PROFILES
15.1. PROTALIX BIOTHERAPEUTICS INC
15.1.1 COMPANY OVERVIEW
15.1.2 FINANCIAL PERFORMANCE
15.1.3 PRODUCT PORTFOLIO
15.2. PFIZER INC
15.2.1 COMPANY OVERVIEW
15.2.2 FINANCIAL PERFORMANCE
15.2.3 PRODUCT PORTFOLIO
15.3. ACTELION PHARMACEUTICALS LTD
15.3.1 COMPANY OVERVIEW
15.3.2 PRODUCT PORTFOLIO
15.3.3 RECENT DEVELOPMENT
15.4. SANOFI SA
15.4.1 COMPANY OVERVIEW
15.4.2 FINANCIAL PERFORMANCE
15.4.3 PRODUCT PORTFOLIO
15.5. TAKEDA PHARMACEUTICAL CO LTD
15.5.1 COMPANY OVERVIEW
15.5.2 FINANCIAL PERFORMANCE
15.5.3 PRODUCT PORTFOLIO
15.5.4 RECENT DEVELOPMENT
1. INTRODUCTION
1.1. MARKET DEFINITION
1.2. PURPOSE OF THE REPORT
1.3. CURRENCY
1.4. LIMITATIONS
1.5. STAKEHOLDERS
2. RESEARCH METHODOLOGY
2.1. RESEARCH SCOPE
2.2. MARKET SEGMENTATION
2.3. RESEARCH APPROACH
2.3.1 TOP-DOWN APPROACH
2.3.2 BOTTOM-UP APPROACH
2.4. PRIMARY RESEARCH
2.5. SECONDARY RESEARCH
2.6. ASSUMPTIONS
3. GLOBAL GAUCHER DISEASE MARKET – EXECUTIVE SUMMARY
3.1. SUMMARY
4. GLOBAL GAUCHER DISEASE MARKET OVERVIEW
4.1. MARKET DYNAMICS
4.1.1 DRIVING FORCES
4.1.1.1 Growing incidence of Gaucher disease
4.1.1.2 Increasing governmental support and growing demand for enzyme
replacement therapy for the treatment of rare diseases
4.1.2 RESTRAINING FACTOR
4.1.2.1 High cost of product and therapies
4.1.3 OPPORTUNITY MATRIX
4.1.3.1 Expansion of product portfolio especially in towards Pharmaceutical Products
5. INDUSTRY INSIGHTS
5.1. PORTER'S FIVE FORCES ANALYSIS
5.1.1 BARGAINING POWER OF SUPPLIER
5.1.2 BARGAINING POWER OF BUYER
5.1.3 THREAT OF SUBSTITUTE
5.1.4 THREAT OF NEW ENTRANT
5.1.5 DEGREE OF COMPETITION
5.2. VALUE CHAIN ANALYSIS
6. GLOBAL GAUCHER DISEASE MARKET, BY PRODUCT
6.1. OVERVIEW
7. GLOBAL GAUCHER DISEASE MARKET, BY INFUSION MODES
7.1. OVERVIEW
8. GLOBAL GAUCHER DISEASE MARKET, BY DISTRIBUTION CHANNEL
8.1. OVERVIEW
9. GLOBAL GAUCHER DISEASE MARKET, BY CLINICAL TYPE
9.1. OVERVIEW
10. NORTH AMERICA GAUCHER DISEASE MARKET
10.1. OVERVIEW
10.1.1.1 North America Market Analysis, By Product Type
10.1.1.2 North America Market Analysis, By Intake Mode
10.1.1.3 North America Market Analysis, By Clinical Types
10.1.1.4 North America Market Analysis, By End-Users
10.2. U.S.
10.2.1.1 U.S. Market Analysis, By Product Type
10.2.1.2 U.S. Market Analysis, By Intake Mode
10.2.1.3 U.S. Market Analysis, By Clinical Types
10.2.1.4 U.S. Market Analysis, By End-Users
10.3. CANADA
10.3.1.1 Canada Market Analysis, By Product Type
10.3.1.2 Canada Market Analysis, By Intake Mode
10.3.1.3 Canada Market Analysis, By Clinical Types
10.3.1.4 Canada Market Analysis, By End-Users
11. LATIN AMERICA GAUCHER DISEASE MARKET
11.1. OVERVIEW
11.1.1.1 Latin America Market Analysis, By Product Type
11.1.1.2 Latin America Market Analysis, By Intake Mode
11.1.1.3 Latin America Market Analysis, By Clinical Types
11.1.1.4 Latin America Market Analysis, By End-Users
11.2. BRAZIL
11.2.1.1 Brazil Market Analysis, By Product Type
11.2.1.2 Brazil Market Analysis, By Intake Mode
11.2.1.3 Brazil Market Analysis, By Clinical Types
11.2.1.4 Brazil Market Analysis, By End-Users
11.3. MEXICO
11.3.1.1 Mexico Market Analysis, By Product Type
11.3.1.2 Mexico Market Analysis, By Intake Mode
11.3.1.3 Mexico Market Analysis, By Clinical Types
11.3.1.4 Mexico Market Analysis, By End-Users
11.4. ARGENTINA
11.4.1.1 Argentina Market Analysis, By Product Type
11.4.1.2 Argentina Market Analysis, By Intake Mode
11.4.1.3 Argentina Market Analysis, By Clinical Types
11.4.1.4 Argentina Market Analysis, By End-Users
12. EUROPE GAUCHER DISEASE MARKET
12.1. OVERVIEW
12.1.1.1 Europe Market Analysis, By Product Type
12.1.1.2 Europe Market Analysis, By Intake Mode
12.1.1.3 Europe Market Analysis, By Clinical Types
12.1.1.4 Europe Market Analysis, By End-Users
12.2. GERMANY
12.2.1.1 Germany Market Analysis, By Product Type
12.2.1.2 Germany Market Analysis, By Intake Mode
12.2.1.3 Germany Market Analysis, By Clinical Types
12.2.1.4 Germany Market Analysis, By End-Users
12.3. UNITED KINGDOM
12.3.1.1 United Kingdom Market Analysis, By Product Type
12.3.1.2 United Kingdom Market Analysis, By Intake Mode
12.3.1.3 United Kingdom Market Analysis, By Clinical Types
12.3.1.4 United Kingdom Market Analysis, By End-Users
12.4. FRANCE
12.4.1.1 France Market Analysis, By Product Type
12.4.1.2 France Market Analysis, By Intake Mode
12.4.1.3 France Market Analysis, By Clinical Types
12.4.1.4 France Market Analysis, By End-Users
12.5. ITALY
12.5.1.1 Italy Market Analysis, By Product Type
12.5.1.2 Italy Market Analysis, By Intake Mode
12.5.1.3 Italy Market Analysis, By Clinical Types
12.5.1.4 Italy Market Analysis, By End-Users
12.6. SPAIN
12.6.1.1 Spain Market Analysis, By Product Type
12.6.1.2 Spain Market Analysis, By Intake Mode
12.6.1.3 Spain Market Analysis, By Clinical Types
12.6.1.4 Spain Market Analysis, By End-Users
12.7. TURKEY
12.7.1.1 Turkey Market Analysis, By Product Type
12.7.1.2 Turkey Market Analysis, By Intake Mode
12.7.1.3 Turkey Market Analysis, By Clinical Types
12.7.1.4 Turkey Market Analysis, By End-Users
12.8. RUSSIA
12.8.1.1 Russia Market Analysis, By Product Type
12.8.1.2 Russia Market Analysis, By Intake Mode
12.8.1.3 Russia Market Analysis, By Clinical Types
12.8.1.4 Russia Market Analysis, By End-Users
13. ASIA PACIFIC GAUCHER DISEASE MARKET
13.1. OVERVIEW
13.1.1.1 Asia Pacific Market Analysis, By Product Type
13.1.1.2 Asia Pacific Market Analysis, By Intake Mode
13.1.1.3 Asia Pacific Market Analysis, By Clinical Types
13.1.1.4 Asia Pacific Market Analysis, By End-Users
13.2. CHINA
13.2.1.1 China Market Analysis, By Product Type
13.2.1.2 China Market Analysis, By Intake Mode
13.2.1.3 China Market Analysis, By Clinical Types
13.2.1.4 China Market Analysis, By End-Users
13.3. INDIA
13.3.1.1 India Market Analysis, By Product Type
13.3.1.2 India Market Analysis, By Intake Mode
13.3.1.3 India Market Analysis, By Clinical Types
13.3.1.4 India Market Analysis, By End-Users
13.4. JAPAN
13.4.1.1 Japan Market Analysis, By Product Type
13.4.1.2 Japan Market Analysis, By Intake Mode
13.4.1.3 Japan Market Analysis, By Clinical Types
13.4.1.4 Japan Market Analysis, By End-Users
13.5. SOUTH KOREA
13.5.1.1 South Korea Market Analysis, By Product Type
13.5.1.2 South Korea Market Analysis, By Intake Mode
13.5.1.3 South Korea Market Analysis, ByClinical Types
13.5.1.4 South Korea Market Analysis, By End-Users
13.6. AUSTRALIA
13.6.1.1 Australia Market Analysis, By Product Type
13.6.1.2 Australia Market Analysis, By Intake Mode
13.6.1.3 Australia Market Analysis, By Clinical Types
13.6.1.4 Australia Market Analysis, By End-Users
14. MIDDLE EAST AND AFRICA (MEA) GAUCHER DISEASE MARKET
14.1. OVERVIEW
14.1.1.1 MEA Market Analysis, By Product Type
14.1.1.2 MEA Market Analysis, By Intake Mode
14.1.1.3 MEA Market Analysis, By Clinical Types
14.1.1.4 MEA Market Analysis, By End-Users
14.2. SOUTH AFRICA
14.2.1.1 South Africa Market Analysis, By Product Type
14.2.1.2 South Africa Market Analysis, By Intake Mode
14.2.1.3 South Africa Market Analysis, By Clinical Types
14.2.1.4 South Africa Market Analysis, By End-Users
14.3. SAUDI ARABIA
14.3.1.1 Saudi Arabia Market Analysis, By Product Type
14.3.1.2 Saudi Arabia Market Analysis, By Intake Mode
14.3.1.3 Saudi Arabia Market Analysis, By Clinical Types
14.3.1.4 Saudi Arabia Market Analysis, By End-Users
14.4. ISRAEL
14.4.1.1 Israel Market Analysis, By Product Type
14.4.1.2 Israel Market Analysis, By Intake Mode
14.4.1.3 Israel Market Analysis, By Clinical Types
14.4.1.4 Israel Market Analysis, By End-Users
14.5. UAE
14.5.1.1 UAE Market Analysis, By Product Type
14.5.1.2 UAE Market Analysis, By Intake Mode
14.5.1.3 UAE Market Analysis, By Clinical Types
14.5.1.4 UAE Market Analysis, By End-Users
15. COMPANY PROFILES
15.1. PROTALIX BIOTHERAPEUTICS INC
15.1.1 COMPANY OVERVIEW
15.1.2 FINANCIAL PERFORMANCE
15.1.3 PRODUCT PORTFOLIO
15.2. PFIZER INC
15.2.1 COMPANY OVERVIEW
15.2.2 FINANCIAL PERFORMANCE
15.2.3 PRODUCT PORTFOLIO
15.3. ACTELION PHARMACEUTICALS LTD
15.3.1 COMPANY OVERVIEW
15.3.2 PRODUCT PORTFOLIO
15.3.3 RECENT DEVELOPMENT
15.4. SANOFI SA
15.4.1 COMPANY OVERVIEW
15.4.2 FINANCIAL PERFORMANCE
15.4.3 PRODUCT PORTFOLIO
15.5. TAKEDA PHARMACEUTICAL CO LTD
15.5.1 COMPANY OVERVIEW
15.5.2 FINANCIAL PERFORMANCE
15.5.3 PRODUCT PORTFOLIO
15.5.4 RECENT DEVELOPMENT
